SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-006663
Filing Date
2021-05-10
Accepted
2021-05-10 16:06:05
Documents
54
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q btai-20210331x10q.htm 10-Q 1159720
2 EX-31.1 btai-20210331ex3111cf24e.htm EX-31.1 17915
3 EX-31.2 btai-20210331ex312cc8c25.htm EX-31.2 17015
4 EX-32.1 btai-20210331ex3218903bd.htm EX-32.1 10381
5 EX-32.2 btai-20210331ex322c9253d.htm EX-32.2 8749
6 GRAPHIC btai-20210331x10q006.jpg GRAPHIC 69208
  Complete submission text file 0001558370-21-006663.txt   3737231

Data Files

Seq Description Document Type Size
7 EX-101.INS btai-20210331.xml EX-101.INS 513629
8 EX-101.SCH btai-20210331.xsd EX-101.SCH 28755
9 EX-101.CAL btai-20210331_cal.xml EX-101.CAL 32415
10 EX-101.DEF btai-20210331_def.xml EX-101.DEF 87774
11 EX-101.LAB btai-20210331_lab.xml EX-101.LAB 291005
12 EX-101.PRE btai-20210331_pre.xml EX-101.PRE 206758
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

IRS No.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38410 | Film No.: 21907147
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences